No Added Benefit From Chemo in This Breast Cancer Subtype No Added Benefit From Chemo in This Breast Cancer Subtype
Adding chemotherapy to endocrine therapy for women with ER-positive, HER2-negative invasive lobular carcinoma does not improve survival outcomes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 28, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Highlights in HR-Positive Breast Cancer From SABCS 2023 Highlights in HR-Positive Breast Cancer From SABCS 2023
Highlights in HR+/HER2- breast cancer from SABCS 2023 include the INAVO120 trial of novel PI3K inhibitor inavolisib and 3-year follow-up data from the NATALEE trial, as reported by Dr Harold Burstein.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news
The Clinical Implications of Findings From SABCS 2023 The Clinical Implications of Findings From SABCS 2023
Dr Tarah J. Ballinger explores the impact of the INAVO120 study and the NATALEE trial on HR+/HER2- metastatic breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 27, 2023 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer
Older patients with advanced HER2+ breast cancer do not experience a survival benefit with trastuzumab emtansine vs standard-of-care combination therapy, although toxicity is improved, a trial shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
SABCS 2023: Highlights in HR+/HER2- Breast Cancer SABCS 2023: Highlights in HR+/HER2- Breast Cancer
Tarah J. Ballinger, MD, provides her biggest takeaways from SABCS 2023 in HR+/HER2- breast cancer.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2023 Category: Consumer Health News Tags: None MDAngle Source Type: news
Imagion highlights MRI contrast agent study at SABCS
Imagion Biosystems presented positive results from a phase I trial evaluating its experimental MRI contrast agent at the recent San Antonio Breast Cancer Symposium.The company’s MagSense HER2 Imaging Agent (MSH2IA) was safe and well-tolerated in 13 patients diagnosed with HER2+ breast cancer, according to the findings. MSH2IA was designed as an adjunct to MRI for the assessment of axillary lymph node metastasis in patients diagnosed with HER2+ primary breast cancer.The trial met its endpoints of safety and tolerability, and showed that blinded radiologists may be able to distinguish suspicious lymph nodes that are infilt...
Source: AuntMinnie.com Headlines - December 13, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Bispecific Antibody Combination Active in Metastatic HR+/HER2+ Breast Cancer
(MedPage Today) -- SAN ANTONIO -- Combination therapy including a bispecific antibody targeting HER2 showed durable activity in patients with previously treated metastatic hormone receptor-positive (HR+)/HER2+ breast cancer, a preliminary clinical... (Source: MedPage Today OB/GYN)
Source: MedPage Today OB/GYN - December 10, 2023 Category: OBGYN Source Type: news
Add-On Inavolisib Ups PFS in PIK3CA-Mutated Breast Cancer
(MedPage Today) -- SAN ANTONIO -- The addition of inavolisib to palbociclib (Ibrance) plus fulvestrant (Faslodex) boosted progression-free survival (PFS) in patients with recurrent PIK3CA-mutated HR-positive, HER2-negative advanced breast cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 10, 2023 Category: Hematology Source Type: news
Menarini Group apresenta novos dados de sobreviv ência livre de progressão relacionados ao estudo clínico EMERALD sobre o ORSERDU® (Elacestrant) com subgrupos de pacientes clinicamente relevantes com câncer de mama metastático (CMM) ER+, HER2- com mutações no gene ESR1 no SABCS 2023
Essa nova análise post hoc do ensaio EMERALD de Fase 3 avaliou o elacestrant na população sensível ao sistema endócrino (duração de pelo menos 12 meses do inibidor de CDK4/6) com tumores que abrigam mutações no gene ESR1. Essa análise mostra uma melhora clinicamente significativa na... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 10, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Die Menarini Group pr äsentiert auf dem SABCS 2023 neue progressionsfreie Überlebensdaten aus der klinischen EMERALD-Studie zu ORSERDU® (Elacestrant) in klinisch relevanten Untergruppen von Patienten mit ER+, HER2- metastasiertem Brustkrebs (Metastatic Breast Cancer, mBC) mit ESR1-Mutationen
Diese neue Post-hoc-Analyse der Phase-3-EMERALD-Studie untersuchte Elacestrant in der endokrin sensitiven Population (CDK4/6-Inhibitor-Dauer von mindestens 12 Monaten) mit Tumoren, die ESR1-Mutationen aufweisen. Diese Analyse weist auf eine klinisch bedeutsame Verbesserung des... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Il Gruppo Menarini presenta a SABCS 2023 nuovi dati dallo studio clinico EMERALD su ORSERDU ® (elacestrant) sulla sopravvivenza libera da progressione in sottogruppi clinicamente rilevanti di pazienti con carcinoma mammario metastatico (mBC) ER+, HER2- con mutazioni di ESR1
Questa nuova analisi post-hoc dello studio di fase 3 EMERALD ha valutato elacestrant nella popolazione endocrino-sensibile (durata dell'inibitore delle CDK4/6 di almeno 12 mesi) affetta da carcinomi con mutazioni di ESR1. Questa analisi mostra un miglioramento clinicamente significativo... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Menarini Group presenta nuevos datos de supervivencia libre de progresi ón del estudio clínico EMERALD de ORSERDU® (elacestrant) en pacientes con cáncer de mama metastásico (CMM) ER+, HER2- con mutaciones en ESR1 en el SABCS 2023
Este nuevo análisis post hoc del ensayo de fase 3 EMERALD evaluó elacestrant en la población con sensibilidad a la terapia endocrina (duración del inhibidor de CDK4/6 de al menos 12 meses) con tumores que albergaban mutaciones en el gen ESR1. Este análisis muestra una mejora clínicamente... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - December 9, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
Trop-2 Drug Conjugate May Trump Chemo in HR+, HER2- BRCA Trop-2 Drug Conjugate May Trump Chemo in HR+, HER2- BRCA
If approved, the ADC would join sacituzumab govitecan (Trodelvy, Gilead) as agents that target trophoblast cell-surface antigen-2 (Trop-2), which is universally expressed in breast cancer.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Media News - December 8, 2023 Category: Pharmaceuticals Source Type: news
Roche's Kadcyla is the first targeted therapy to show significant overall survival benefit in people with HER2-positive early-stage breast cancer with residual invasive disease after neoadjuvant treatment
Phase III KATHERINE results reinforce Kadcyla as the standard of care for this population, with more than 82,000 people treated to date1,2Long-term data also showed continued benefit in invasive disease-free survival for adjuvant Kadcyla compared to Herceptin in this study2These data will be presented as an oral presentation at the 2023 San Antonio Breast Cancer Symposium and included in the official press programmeBasel, 8 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive long-term follow-up data from the pivotal, phase III KATHERINE study in people with HER2-positive early-stage breast cancer (e...
Source: Roche Investor Update - December 8, 2023 Category: Pharmaceuticals Source Type: news
